# Blood glucose level lowering agent.

## Abstract
A method of lowering the blood glucose level in mammals and a blood glucose level lowering agent are described. The method comprises administering an enzyme capable of synthesizing sparingly digestible saccharides from easily digestible saccharides. The blood glucose level lowering agent comprises the enzyme capable of synthesiz ing sparingly digestible saccharides from easily digestible saccharides and a glucosidase inhibiting agent.

## Claims
WHAT IS CLAIMED IS 1. A method of lowering the blood glucose level in mammals, comprising orally administering an enzyme capable of synthesizing sparingly digestible saccharides from easily digestible saccharides. 2. A method as in Claim 1, wherein the enzyme is administered together with a glucosidase inhibiting agent. 3. A method as in Claim 1 or 2 , wherein the enzyme synthesizes sparingly digestible polysaccharides or oligosaccharides from easily digestible monosaccharides, oligosaccharides, or polysaccharides. 4. A method as in Claim 1 or 2, wherein the enzyme is at least one member selected from dextransucrase and cyclodextrin synthesizing enzymes. 5. A method as in Claim 4, wherein the dextransucrase is produced by a bacterium selected from the genera Leuconostoc and Streptococcus, and the cyclodextrin synthesizing enzyme is produced by a bacterium selected from the genera Bacillus andKlebsiella. 6. A method as in Claim 1 or 2, wherein the enzyme is dextransucrase produced by a strain belonging to the genus Streptococcus. 7. A method as in Claim 1 or 2, wherein the enzyme is a cyclodextrin synthesizing enzyme produced by a strain belonging to the genus Bacillus. 8. A method as in Claim 1, wherein the enzyme is orally administered in an amount of 1 to 100 mg day. 9. A method as in Claim 2, wherein the mixture of the enzyme and the glucosidase inhibiting agent is orally administered in an amount of 1 to 100 mg day. 10. A blood glucose level lowering agent comprising an enzyme capable of synthesizing sparingly digestible saccharides from easily digestible saccharides and a glucosidase inhibiting agent. 11. A blood glucose level lowering agent as in Claim 10, wherein the glucosidase inhibiting agent inhibits the amylase, sucrase, and maltase actions. 12. A blood glucose level lowering agent as in Claim 10, wherein the weight ratio of the enzyme to the glucosidase inhibiting agent is from 1 20 to 20 1. 13. Use of an enzyme capable of synthesizing sparingly digestible saccharides from easily digestible saccharides for a blood glucose level lowering agent. 14. Use of an enzyme as in Claim 13, wherein the enzyme is selected from dextransucrase and cyclodextrin synthesizing enzymes. WHAT IS CLAIMED IS 1. A blood glucose level lowering agent comprising an enzyme capable of synthesizing sparingly digestible saccharides from easily digestible saccharides. 2. A blood glucose level lowering agent comprising an enzyme capable of synthesizing sparingly digestible saccharides from easily digestible saccharides and a glucosidase inhibiting agent. 3. An agent as in Claim 1 or 2, wherein the enzyme synthesizes sparingly digestible polysaccharides or oligosaccharides from easily digestible monosaccharides, oligosaccharides, or polysaccharides. 4. An agent as in Claim 1, 2 or 3, wherein the enzyme is at least one member selected from dextransucrase and cyclodextrinsynthesizing enzymes. 5. An agent as in Claim 4, wherein the dextransucrase is pro duced by a bacterium selected from the genera Leuconostoc and Streptococcus, and the cyclodextrin synthesizing enzyme is produced by a bacterium selected from the genera Bacillus and Klebsiella. 6. An agent as in Claim 1 or 2, wherein the enzyme is dextransucrase produced by a strain belonging to the genus Strop to coccus. 7. An agent as in Claim 1 or 2, wherein the enzyme is a cyclodextrin synthesizing enzyme produced by a strain belonging to the genus Bacillus. 8. An agent as in Claim 1, wherein the enzyme can be orally administered in an amount of 1 to 100 mg day. 9. An agent as in claim 2, wherein the mixture of the enzyme and the glucosidase inhibiting agent can be orally administered in an amount of 1 to 100 mg day. 10. A blood glucose level lowering agent as in claim 2, wherein the glucosidase inhibiting agent inhibits the amylase, sucrase, and maltase actions. 11. A blood glucose level lowering agent as in claim 2, wherein the weight ratio of the enzyme to the glucosidase inhibi ting agent is from 1 20 to 20 1. 12. Use of an enzyme capable of synthesizing sparingly digestible saccharides from easily digestible saccharides for a blood glucose level lowering agent. 13. Use of an enzyme as in claim 12 , wherein the enzyme is selected from dextransucrase and cyclodextrin synthesizing enzymes.

## Description
BLOOD GLUCOSE LEVEL LOWERING AGENTS FIELD OF THE INVENTION The present invention relates to a method of lowering the blood glucose level and a blood glucose level lowering agent Chypoglycemic agent . BACKGROUND OF THE INVENTION Recently, metabolic diseases, such as diabetes, obesity and arteriosclerosis, resulting from an increase in a blood glucose level due to excessive intake of digestible saccharides, particularly starch and sucrose, have been increasing. Such unbalanced eating habits of intaking digestible saccharides are also responsible for digtive diseases, such as diarrhea, gastroenteric catarrh and abnormal zymosis in the bowel. Completely satisfactory drugs for these diseases have not yet been discovered, and it has long been desired to develop improved drugs. SUMMARY OF THE INVENTION It has now been discovered that an enzyme capabl e of synthesizing sparingly digestible saccharides, such as polysaccharides and oligosaccharides e.g., cyclodextrin , from easly digestible saccharides, such as monosaccharides, oligosaccharides Ce.g., dextrin, maltose, isomaltose and sucrose and polysaccharides,. lowers blood glucose levels in mammals including human beings, and has excellent effects in preventing and treating metabolic and digestive diseases. As a result of an extensive search for a substance having a blood glucose level lowering activity, it has further been discovered that when an enzyme capable of synthesizing sparingly digestible saccharides. from easily digestible saccharides is used in combination with a glucosidase inhibiting agent which has already been known to have the effect of lowering a blood glucose level, the blood glucose level lowering effect is enhanced synergistically compared to when they are used separately. Thus, the present invention provides, in one embodiment, a method of lowering the blood glucose level in mammals comprising orally administering an enzyme capable of synthesizing sparingly digestible saccharides from easily digestible saccharides, and in another embodiment, a blood glucose level lowering agent containing an enzyme capable of synthesizing sparingly digestible saccharides from easily digestible saccharides and a glucosidase inhibiting agent. DETAILED DESCRIPTION OF THE INVENTION Enzymes which can be used in the invention, i.e., having the ability to synthesize sparingly digestible saccharides from easily digestible saccharides include Dextransucrase, produced by the generaLeuconostoc, Streptococcus, and Betabacterium, which synthesizes dextran from sucrose Dextran 6 glycociltransferase, produced by the genus Acetobacter, which synthesizes dextran from amylodextrin Levansucrase, produced by the genera Bacillus, Acetobacter, Pseudomonas, and Xanthomonas, which synthesizes levan from sucrose Amylomaltase, produced by the genus Escherichia, which synthesizes amylose from maltose Amylosucrase, produced by the genus Neisseria, which synthesizes amylopectinlike polysaccharide from sucrose and cyclodextrinsynthesizing enzymes, produced by the genera Bacillus and Klebsiella, which synthesize cyclodextrin C, ss and y types from starch or sucrose. Of these enzymes, dextransucrase and cyclodextrin synthesizing enzymes are particularly preferred. These enzymes are all known and can be prepared by known procedures Ce.g., W. Pigman andD. Horton, Ed., The Carbohydrates. Chemistry and Biochemistry, Academic Press, pp. 302 373 1970 S.P. Colowick and N.O. Kaplan, Ed., Methods in Enzymology, AcademicPress, Vol. 1, pp. 178 192 1955 , and Vol. 5, pp. 140 155 1962 E.F. Neufeld and V.Ginsberg, Ed., Methods inEnzymology, Vol. 8, pp. 500 505 t1966 T.J. Montville et awl., Advances in Applied Microbiology, Academic Press,Vol. 24, pp. 55 84 1978 H. Horikoshi and N. Nakamura, Kagaku to Seibutsu, Vol. 17, pp. 300 305 1979 K. Matsuda and M. Kobayashi, Hakko to Kogyo, Vol. 36, pp. 11 21 1978 S. Kobayashi and K. Kainuma, Hakko toKogyo, Vol. 36, pp. 176 183 1978 and T. Tanaka,S. Oi, M. Iizuka, and T. Yamamoto, Agric. Biol. Chem.,Vol. 42, pp. 323 326 1978 . In addition, various polysaccharide synthesizing enzymes or enzyme systems produced by bacteria, yeast and fungi, which synthesize sparingly digestible polysaccharides e.g., cellulose, pullulan, nigeran, Bglucans and curdrun , can be used in the invention.Furthermore, enzymes synthesizing polysaccharides of plants, such as hemi cellulose, pectin, and rubber like polysaccharides enzymes synthesizing various seaweed polysaccharides and animal enzymes synthesizing mucopolysaccharides see A. Harada and A. Misaki, SogoTatorui Kagaku, Kodansha, Japan, pp. 3 436 1974 can be used in the invention. These enzymes may be used in either purified or crude form. Furthermore, either dead cells or living cells containing these enzymes can be used. The toxicity of these enzymes is very low LD50 1 g kg mice, P.O. . The glucosidase inhibiting agent which is used in the other embodiment of the invention inhibits the amylase, sucrase and maltase actions. Examples of such glucosidase inhibiting agents include Bay g 5421, TAI,S AI, S GI, Haim, Nozilimycin, and Tris. These glucosidase inhibiting agents are known and can be prepared by the known methods see D.D. Schmidt,W. Frommer, B. Junge, L. Muller, W. Wingender andE. Truscheit, Naturwissenschaften, Vol. 64, pp. 535 536 1977 S. Namiki, K. Kamikori, T. Nagate, K. Sugita,H. Hara, E. Mori, S. Omura and M. Ozeki, Denpun Kagaku,Vol. 26, pp. 134 144 1979 and Vol. 27, p. 107 1980 S. Murao, K. Oyama, H. Murai, AW Goto, Y. Matsui,K. Fukuhara, S. Miyata, M. Sumida and M. Arai, DenpunKagaku, Vol. 26, pp. 157 164 1979 S. Ueda, Y. Kiba and H.Sain, Denpun Kagaku, Vol. 26, pp. 145 156 1979 T. Niwa, T. Tsuruoka, S. Inoue and T. Niida, Amylase..Symposium, Vol. 7, p. 91 1972 W. Puls and U. Keup,Metabolism, Vol. 24, pp. 93 98 C1974 S. Murao andK. Ohyama, Agric. Biol. Chem., Vol. 39, p. 2271 1975 S. Murao and K. Ohyama, Agric. Biol. Chem., Vol. 41, pp. 919 and 2221 1977 S. Murao and S. Miyata, Agric.Biol. Chem., Vol. 44, p. 219 C1980 S. Murao, A. Goto,Y. Matsui and K. Ohyama, Agric. Biol. Chem., Vol. 44, p. 1679 C1980 and T. Niwa, S. Inoue, T. Tsuruoka,Y. Koaze and T. Niida, Agric. Biol. Chem., Vol. 34, p. 966 1970 . These glucosidase inhibiting agents may be used in either purified or crude form. The toxicity of these inhibiting agents is very low CLD50 500 mg kg, mice,P.O. . Where the enzyme capable of synthesizing sparingly digestible saccharides from easily digestible saccharides is used in combination with the glucosidaseinhibiting agent, the composition ratio can be varied within a wide range. It is most preferred, however, that the weight ratio of the enzyme to the glucosidaseinhibiting agent is from 1 20 to 20 1. The blood glucose level lowering agent used according to the invention is either the enzyme alone, or a combination of the enzyme and the glueosidassew biti4g. agent, which can be prepared simply by mixing them. The blood glucose level lowering agent can be converted into a powder, a capsule, a tablet or the like, along with suitable excipients. Furthermore, it may contain a stabilizer. Moreover, it can be used in combination with other agents to prevent and treat metabolic and digestive diseases. The blood glucose level lowering agent of the invention can be administered orally, lntraperitoneally, or intravenously. In general, oral administration is suitable. Although the amount of the blood glucose level lowering agent the enzyme alone or a mixture of the enzyme and the glucosidase inhibiting agent being administered varies depending on the type of disease, extent, and so forth, it is usually from about 0.2 to 2,000 mg day, and in particular, it is preferred that the blood glucose level lowering agent is administered orally in an amount of 1 to 100 mg day. Hereinafter, the invention is described in greater detail by reference to the following examples. EXAMPLE 1 i A dextransucrase producing strain, Leuconostoc mesenteroides NRRL B 1299, was aerobically cultivated at 260C for 24 hours by the use of a culture medium containing 25 of sucrose, 2 of corn steep liquor, 0.2 ofK2HPO4, 0.018 of MgSO487H2O, 0.00l of FeSO4.7H2O, 0.0018 of MnCt4H2O, and 0.0018 of NaCt, and having a pH of 7.4. After the cultivation was completed, the medium was filtered to separate it into a filtrate and a solid fraction. Solid ammonium sulfate was added to a part of the filtrate with stirring at room temperature to 30 saturation, followed by further stirring for 30 minutes.Precipitates formed were collected by centrifugation and discarded. Thereafter, to the resulting liquid was added ammonium sulfate to 708 saturation, and precipi tates thus formed were collected by centrifugation. The precipitates were dissolved in a 0.01 M phosphate buffer at pH 6.7, dialyzed overnight against the buffer and freeze dried to obtain Enzyme A. A part of the remaining filtrate was directly freeze dried to obtain a crude enzyme Enzyme B . A part of the solid fraction was treated with acetone at low temperatures to obtain an acetone dried cell fraction Enzyme C . The remaining solid fraction was ground along with silica sand at a low temperature and was subjected to high speed centrifugal separation.The supernatant liquid was withdrawn and freeze dried to obtain Enzyme D. ii Male ICR mice t18 to 21 g were divided into groups o f five mice, deprived of food for 24 hours and orally administered with 2.5 g kg of sucrose. At the same time, each of the above prepared enzymes was orally administered in an amount of 100 mg kg. After 15 minutes, 30 minutes, 1 hour and 3 hours, blood samples werecollected, and the blood glucose level was determined.The results are shown in Table 1. It can be seen from Table 1 that with the groups to which Enzymes A, B, C and D were administered, the blood glucose level was markedly reduced compared with the control group to which sucrose alone was administered. The values in Table 1 are average values for each group of five mice. TABLE 1 Blood Glucose Level mg dt After After After After 15 30 Group Min. Min. I Control 291 226 183 152Group administered 138 157 121 129 with Enzyme AGroup administered 169 183 139 135 with Enzyme BGroup administered 196 206 167 136 with Enzyme CGroup administered 170 181 160 133 with Enzyme D EXAMPLE 2 i A Levansucrase producing strain, Bacillus subtilis BS 5 stored by Dr. Delaporte PCB, Paris,France , was cultivated on a culture medium comprising sucrose 65, 0.1 M KNO3, 0.07 M K2HPO4, 0.3 M KH2PO4, 0.5 mM MgSO4, 0.05 mM Fe2tS04 3, 0.05 mM ZnSO4, 0.01 mM MnSO4, and 1 mM CaCt2 at 300C under aerobic conditions.The cultivation was stopped after 48 hours, and a filtrate was obtained by filtration. The pH of the filtrate was adjusted to 5.5, and an equal amount of acetone was added thereto while stirring and cooling. Precipitates formed were collected by centrifugal separation, fully washed with acetone, and dried to obtain a dry powder Enzyme E . ii The influences of Enzyme E on the blood glucose level was examined by the same method as inExample 1. The results are shown in Table 2. It can be seen from Table 2 that the group administered with Enzyme E showed a marked reduction in the blood glucose level compared with the control group. TABLE 2 Blood Glucose Level tmg dt After After After After 15 30 30ter After After Group Min. Min. 1 Hr. 3 Hr. Control 291 226 183 152Group administered 162 182 169 148 with Enzyme B EXAMPLE 3 i An Amylosucrase producing strain, Neisseria Perflava 19 34 stored by H.J. Hehre Albert EinsteinColloge of Medicine, New York, N.Y., U.S.A. , was cultivated aerobically on a culture medium comprising glucose 0.5 , peptone 1 , sodium citrate 0.15 , yeast extract 0.02 , KH2P04 0.05 , and Na2HPO4 0.15 at 370C for 5 days. After the cultivation, an extract containing no cell was obtained and treated with ammonium sulfate to obtain a fraction. The thus obtained fraction was freeze dried to obtain Enzyme F. ii The blood glucose level lowering effect ofEnzyme F was examined by the same method as in Example 1.The results are shown in Table 3. As can be seen fromTable 3, a significant effect was observed. TABLE 3 Blood Glucose Level mg d After After After After 15 30 Group Min. Min. l Hr. 3 Hr. Control 291 226 183 152Group administered 246 196 168 139 with Enzyme F EXAMPLE 4 Ci A cyclodextrin synthesizing enzyme producing strain, Bacillus macerans ATCC 8514, was cultivated on a culture medium pH 6.5 comprising oatmeal 5 , CNH4 2HPO4 0.3 , Na2SO4 0.25, and KCt 0.049, and small amounts of chlorides of Mg, Ca, Mn, Fe Ctrivalent , Zn and Co at 370C for 15 hours under aerobic conditions.The cultivation filtrate was concentrated to 1 10 of the original volume thereof, and an equal amount of acetone was added thereto while cooling. Preclpitates formed were collected, dissolved in a small amount of water, and freeze dried to obtain Enzyme G. ii The blood glucose level lowering effect ofEnzyme G was examined by the same method as in Example 1 with the exception that 1 g kg of starch was used in place of the sucrose. The results are shown in Table 4.As can be seen from Table 4, a significant effect was observed. TABLE 4 Blood Glucose Level mg dt After After 15 30 After After Group Min. Min. 1 Hr. 3 Hr.Control 221 206 159 136Group administered 166 158 134 132 with Enzyme G EXAMPLE 5 A bacterial strain having the ability to produce a cyclodextrin synthesizing enzyme, Bacillus sp.ATCC 21783, was cultivated on a culture medium comprising soluble starch 25, peptone 0.5t, yeast extract 0.5 , K2HPO4 0.1t, MgSO4.7H2O 0.02 , and Na2CO3 18 at 370C for 3 days under aerobic conditions. The culturedbroth was filtered to obtain a filtrate. To the thus obtained filtrate was added cold acetone to form precipitates.The precipitates were collected and freeze dried to obtain a crude enzyme CEnzyme H . The blood glucoselevel lowering effect of Enzyme H.was examined by the same method as in Example 4. The results are shown inTable 5. As can be seen from Table 5, a significant effect was observed. TABLE 5 Blood Glucose Level mg dt Atter Atter After After 15 30 Group Min. Min. 1 Hr. 3 Hr. Control 221 206 159 136Group administered 159 142 133 129 with Enzyme H EXAMPLE 6 A control group Cfive mice of DDYF male mice was bred for 2 weeks with a test food comprising sucrose 69.9 , casein 20 , olive oil 5 , an inorganic salt mixture 4 , a vitamin mixture 1 , and choline chloride 0.18. On the other hand, a test group Cfive mice was administered with Enzyme B prepared in Example 1 in an amount of 100 mg kg day while breeding with the same test food as used above. After 2 weeks, blood samples were collected, and the amount of neutral fat in serum was determined by the usual method as described in I. Kanai and M. Kanai,Rinsho Kensaho Teian, Kinbara Shuppan, Edit. 27, VII 66 1975 . With the control group, the amount was 218 mgldt, whereas with the test group, 136 mg dt, and it can thus be seen that the value is markedly reduced by the administration of Enzyme B. The values are average values for each group of five mice. EXAMPLE 7 Ci A dextransucrase producing strain, Streptococcus . mutans 20623 FERM BP No. 57 , was inoculated on a brain heart infusion broth Eiken Cproduced by Eiken KagakuCo., Ltd. and aerobically cultivated thereon at 370C for 18 hours. After the cultivation was completed, the cultured broth was filtered to obtain a filtrate. The thus obtained filtrate was adjusted to 60t saturation by adding ammonium sulfate. Precipitates formed were collected by centrifugation. The precipitates were then dissolved in a 0.01 M phosphate buffer at pH 6.7, dialyzed overnight against the buffer and freeze dried to obtain Enzyme I. Cii Male wistar rats C142 to 151 g Cgroups of six rats were deprived of food for 24 hours. Enzyme I was orally administered in an amount of 10 mg kg, and, at the same time, sucrose was orally administered in an amount of 2 g kg. 30 minutes after the administration, blood samples were collected and the blood glucose level was measured. With the control group to which sucrose alone was administered, the blood glucose level was 171 mg dLt whereas the blood glucose level of the test group to which Enzyme I was administered was markedly reduced to 127 Fg dt Can average blood glucose value for each group of stx rats . EXAMPLE 8 Ci A dextransucrase producing strain, Streptococcus salivarius IFO 13956, was inoculated on a brain heayt infusion broth Eiken and aerobically cultivated thereon at 370C for 18 hours. After the cultivation was completed, the cultured broth was filtered to obtain a filtrate. The thus obtained filtrate was adjusted to 60 saturation by adding ammonium sulfate. Precipitates thus formed were collected, dialyzed with a 0.01 M phosphate buffer, and freeze dried to obtain Enzyme J. The blood glucose level lowering effect ofEnzyme J was determined by the same method as in Example 7 with the exception that the amount of Enzyme J administered was changed to 30 mg kg. With the control group to which sucrose alone was added, the blood glucose level after 30 minutes was 172 mg dt, whereas the blood glucose level of the group to which Enzyme J was administered was significantly reduced to 138 mg dt an average blood glucose value for each group of six rats . EXAMPLE 9 i A cyclodextrin synthesizing enzyme producing strain, Bacillus macerans 17011 tFERM BP No. 56 , was inoculated on a culture CpH 7.5 comprising glucose 1.0 , starch 1.0 , peptone 1.0t, meat extract 0.5 , and NaCt 0.5 and cultivated at 320C for 24 hours to provide a seed solution. This seed solution was inoculated on a fermentation medium CpH 7.5 comprising bran 3.0t, ammonium sulfate 0.5 , and CaCO3 0.5t in a proportion of 5 and cultured at 370C for 48 hours while aerating and stirring by the use of a 20 liter volute JarFermentor . After the cultivation was completed, the cultured broth was filtered to obtain a filtrate.The thus obtained filtrate was cooled, and starch was added thereto in an amount of 1 100 tw v of the filtrate. The resulting mixture was stirred at 5tC for 20 hours to allow the cyclodextrin synthesizing enzyme to be adsorbed on the starch. Then, the mixture was subjected to centrifugal separation to separate the starch with the enzyme adsorbed thereon. The starch with the enzyme adsorbed thereon was freeze dried to obtain Enzyme K. A part of the freeze dried powder Enzyme K was taken, and water was added thereto in an amount of 5 1 v w of the freeze dri ed powder. The mixture was stirred for 30 minutes while heating at 500C and filtered. The filtrate thus obtained was again freezedried to obtain Enzyme L. ii Male wistar rats 138 to 147 g Cgroups of six rats were deprived of food for 24 hours. At the end of the period, starch was orally administered in an amount of 1 g kg, and at the same time, Enzymes K and L prepared above were administered, respectively, 30 minutes after the administration, blood samples were collected, and the blood glucose level was determined. The results are shown in Table 6 1. It can be seen from Table 6 1 that with the group to which Enzyme K or L was administered, the blood glucose level was significantly lowered compared with the control group to which starch alone was administered. TABLE 6 1 Blood Glucose Level Group after 30 Minutes mg dg Control 175 Group administered with 134 Enzyme K 30 mg kg Group administered with 129 Enzyme L 1 mg kg 129 The value is an average value for each group of six rats. iii In the same manner as in Cii above except that 2 g kg of sucrose was orally administered in place of starch, the effects of Enzyme K and Enzyme L were examined. The results are shown in Table 6 2. As can be seen from Table 6 2, with the group to which Enzyme K or Enzyme L was administered, the blood glucose level was markedly reduced compared with the control group to which only sucrose was administered. TABLE 6 2 Blood Glucose Level Group after 30 Minutes CmgIdt Control 172 Group administered with 141 Enzyme K 30 mg kg Group administered with 138 Enzyme L Cl mg kg The blood glucose level is an average value for each group of six rats. EXAMPLE 10 Ci A cyclodextrin synthesizing enzyme producing strain, Bacillus stearothermophilus IAM 1035, was inoculated on a culture medium CpH 7.5 containing glucose 1.0 , starch 1.0 , peptone 1.0 , meat extract 0.5S, and NaCt 0.58 and aerobically cultivated at 400C for 48 hours. After the cultivation was completed, the cultured broth was filtered.The thus obtained filtrate was cooled, and starch was then added thereto in an amount of 1 100 tw v of the filtrate. The resulting mixture was stirred for 12 hours while cooling at 50C to allow the cyclodextrin synthesizing enzyme to be adsorbed on the starch. The starch with the enzyme adsorbed thereon was separated by centrifugal separation and freeze dried to obtain Enzyme M. ii The blood glucose level lowering effect ofEnzyme M was examined by the same method as in Example 9 With the control group to which starch alone was administered, the blood glucose level after 30 minutes was 170 mg dt, whereas the blood glucose level of the group to which Enzyme M was administered in an amount of 100 mg kg was significantly reduced to 137 mg dt Cthe values are average values for each group of six rats . EXAMPLE 11 Ci A dextransucrase producing strain, Leuconostoc mesenteroides NRRL B 1299, was aerobically cultured on a culture medium pH 7.4 containing sucrose 25, corn steep liquor 2 , K2HPO4 0.2 , MgSO4.7H2O 0.01 , FeSO4.7H2O 0.001 , MnCt2 4H2O 0.001 , and NaCt 0.001 at 26 C for 30 hours. After the cultivation was completed, a culture solution was filtered and separated into a filtrate and a cell fraction. A part of the filtrate was treated in the same manner as in the preparation of Enzyme A in Example l ti , whereby Enzyme N was obtained. Cii Male ICR mice C18 to 20 g Cgroups of five mice were deprived of food for 24 hours, and sucrose was orally administered in an amount of 2.5 g kg. At the same time, Enzyme N and a glucosidase inhibiting agent were orally administered under the conditions shown inTable 7. After 15 minutes and 30 minutes, blood samples were collected, and the blood glucose level was determined. The results are shown in Table 7. When Enzyme N is used in combination with Bay g 5421. produced byBayer, West Germany or Tris produced by Merk 4 Co.,U.S.A. , the blood glucose lowering effect is increased compared with the cases that Enzyme N, Bay g 5421 andTris are used separately. TABLE 7 Blood Glucose Level mg dt After After Group 15 Minutes 30 MinutesControl 269 224Enzyme N t40 mg kg 211 195Bay g 5421 2 mg kg 208 201Tris 100 mg kg 220 209Enzyme N t20 mg kg 166 iso Bay g 5421 1 mg kg Enzyme N C20 mg kg 171 159Tris 50 mg kg EXAMPLE 12 i A cyclodextrin synthesizing enzyme producing strain, Bacillus macerans ATCC 8514, was inoculated on a culture medium pH 6.5 comprising oatmeal 5 , NH4 2HPO4 0.3 , Na2SO4 0.2l, KCt 0.04 , and small amounts of the chlorides of Mg, Ca, Mn, Fe trivalent , Zn and Co, and aerobically cultivated at 370C for 15 hours.The culture solution was concentrated to 1 10 of the original volume thereof, and an equal amount of acetone was added while cooling. Precipitates formed were collected, dissolved in a small amount of water, and freeze dried to obtainEnzyme O. ii The blood glucose level lowering effect ofEnzyme O, Bay g 5421, and a combination thereof was examined by the same method as in Example 11 except that 1 g kg of starch was used in place of the sucrose. The results are shown in Table 8. It can be seen from Table 8 that the effect obtained when Enzyme 0 and Bay g 5421 are administered at the same time is much greater than that obtained when they are administered separately. TABLE 8 Blood Glucose Level tmg dt After After Group 15 Minutes 30 MinutesControl 246 203Enzyme 0 50 mg kg 193 181Bay g 5421 C2 mg kg 201 178Enzyme O C25 mg kg 16Z Bay g 5421 Ci mg kg EXAMPLE 13 Ã¬ A dextransucrase producing strain, Streptococcus mutans 6715 deposited in Kokuritsu Yobo Eisei Kenkyu Jo,Shika Eisei Bu Tokyo , was inoculated on a brain heart infusion broth medium produced by Nippon Seiyaku Co.,Ltd. and cultivated aerobically at 370C for 18 hours.The cultured broth was filtered, and the resulting filtrate 960 mt was adjusted to 605 saturation by adding ammonium sulfate. Precipitates formed were collected, dissolved in a small amount of a physiological saline solution, and dialyzed overnight against the physiological saline solution to obtain Enzyme P 40 ml . ii The blood glucose level lowering effect ofEnzyme P, Bay g 5421, Tris, and combinations thereof was examined by the same method as in Example 11. The results are shown in Table 9. The effect obtained whenEnzyme P is used in combination with Bay. g 5421 or Tris is much greater than those obtained when they are administered separately. TABLE 9 Blood Glucose Level Cmg dt After After Group 15 Minutes 30 MinutesControl 255 229Enzyme P Cl mt kg 222 201Bay g 5421 2 mg kg 215 204Tris C100 mg kg 233 216Enzyme P 0.5 mt kg 169 150Bay g 5421 C1 mg kg Enzyme P 0.5 mt kg 170 161Tris 50 mg kg EXAMPLE 14 Male wistar rats 140 to 148 g groupsof six rats wer.e deprived of food for 24 hours, and.l g kg of starch was orally administered. At the same time,Enzyme K prepared in Example 9 and a glucosidaseinhibiting agent TAI were orally administered under the conditions shown in Table 10.After 30 minutes, blood samples were collected, and the blood glucose level was determined. The results are shown in Table 10. As can be seen from Table 10, the effect obtained by administering Enzyme K and a glucosidase inhibiting agent TAI in combination was markedly high compare d with those obtained by administering Enzyme K and the glucosidaseinhibiting agent TAI separately. TABLE 10 Blood Glucose Level Group after 30 Minutes Cmg dt Control 162 Enzyme K 5 mg kg 151 Enzyme K 30 mg kg 133 TAI 0.4 mg kg 148 TAI 2 mg kg 136 Enzyme K C5 mg kg 125 TAI 0.4 mg kg PREPARATION EXAMPLE 1 Cyclodextrin synthesizing enzyme 50 mg Enzyme L prepared in Example 9 Fine crystalline cellulose SO mg Corn starch 15 mg ss Cyclodextrin 20 mg Milk sugar 12 mg Polyvinyl pyrrolidone 3 mg total 150 mg The cyclodextrin synthesizing enzyme CEnzyme L Example 9 , fine crystalline cellulose, corn starch, B cyclodextrin, and milk sugar were mixed, and an aqueous solution of polyvinyl pyrrolidone was added thereto as a binder. The resulting mixture was granulated by a conventional method. These granules were placed in a gelatin cured capsule to prepare a capsule. PREPARATION EXAMPLE 2 Cyclodextrin synthesizing enzyme 10 mg Enzyme L in Example 9 Glucosidase inhibiting agent TAI 15 mg Fine crystalline cellulose 55 mg Corn starch 24 mg Milk sugar 20 mg Carboxymethyl cellulose calcium salt 10 mg Polyvinyl pyrrolidone 6 mg Talc 10 mg Ctotal 150 mg The cyclodextrin synthesizing enzyme Enzyme L in Example 9 , glucosidase inhibiting agent TAl, fine crystalline cellulose, corn starch, milk sugar, and carboxymethyl cellulose calcium salt were mixed, and an aqueous solution of polyvinyl pyrrolidone was added thereto as a binder. The resulting mixture was granulated by a conventional method. Then, the talc was added thereto, and the mixture was formed into tablets having a weight of 150 mg. While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.